The conjugate vaccine, called Capvaxive, is meant to protect against 21 strains of the bacteria that most often cause invasive pneumococcal disease in adults 50 and older. The CDC’s Advisory Committee on Immunization Practices will meet later in June to make recommendations on who should receive the single-dose vaccine.
Every year, about 150,000 adults are hospitalized due to pneumococcal pneumonia.
Capvaxive is the first pneumococcal conjugate vaccine designed for adults.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
